FNDC5 and hepatocellular carcinoma: It was also reported that sorafenib-resistant HCC cells upregulated the expression of fibronectin type III domain containing 5 (FNDC5), which in turn activated the PI3K-Akt pathway and promoted translocation of nuclear factor E2-related factor 2 (NRF2) into the nucleus to induce antioxidant response and ferroptosis resistance (Liu et al., 2022a).